Treatment of recurrent suprahyoid cervicofacial lymphangioma with intravenous cyclophosphamide.
OBJECTIVE
Surgical resection of cervicofacial cystic hygromas and lymphangiomas rarely effects complete reduction because of severe anatomic restrictions.


METHODS
With prior knowledge of cyclophosphamide activity against lesions of this type, a formal trial of cyclophosphamide was initiated.


RESULTS
Overall dose escalation therapy resulted in 50% reduction in mass without recurrence after cessation of therapy and with minimal and readily reversible toxicity.


CONCLUSIONS
The favorable responses to cyclophosphamide in this study suggest that a prospective randomized trial should be initiated. Certainly, children who have airway and/or esophageal compromise who have failed surgical therapies should be considered for cyclophosphamide treatment.
Turner
C
C
Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32610-0296.
Gross
S
S
D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D006928:Hyoid Bone; D007262:Infusions, Intravenous; D018191:Lymphangioma, Cystic / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local; D014057:Tomography, X-Ray Computed
D003520:Cyclophosphamide